Exelixis, Inc. (EXEL)
Automate Your Wheel Strategy on EXEL
With Tiblio's Option Bot, you can configure your own wheel strategy including EXEL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EXEL
- Rev/Share 8.2457
- Book/Share 7.6434
- PB 5.5734
- Debt/Equity 0.0878
- CurrentRatio 3.4991
- ROIC 0.24
- MktCap 11617360800.0
- FreeCF/Share 2.9155
- PFCF 14.2923
- PE 18.4551
- Debt/Assets 0.066
- DivYield 0
- ROE 0.2935
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | EXEL | Wells Fargo | Overweight | Equal Weight | -- | $36 | Feb. 24, 2025 |
| Upgrade | EXEL | Morgan Stanley | Equal Weight | Overweight | $30 | $40 | Jan. 27, 2025 |
| Downgrade | EXEL | Oppenheimer | Outperform | Perform | -- | -- | Jan. 24, 2025 |
| Downgrade | EXEL | BMO Capital Markets | Outperform | Market Perform | $36 | $40 | Dec. 20, 2024 |
| Downgrade | EXEL | BofA Securities | Buy | Neutral | $35 | $39 | Dec. 17, 2024 |
| Reiterated | EXEL | RBC Capital Mkts | -- | Outperform | $30 | $34 | Oct. 16, 2024 |
| Initiation | EXEL | UBS | -- | Neutral | -- | $30 | Sept. 19, 2024 |
News
Top 4 Value Stocks With Impressive PEG Ratios to Buy Now
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Here are the four discounted PEG-based value stocks that qualify our screening criteria- URBN, XRAY, LTM and EXEL.
Read More
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock?
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.
Read More
EXEL vs. ARGX: Which Stock Is the Better Value Option?
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.
Read More
Product Performance, Big Money Lift Exelixis
Published: May 23, 2025 by: FXEmpire
Sentiment: Positive
Shares of Exelixis, Inc. (EXEL), an oncology-focused biopharmaceutical firm, boosted by Big Money inflows.
Read More
Exelixis (EXEL) is a Great Momentum Stock: Should You Buy?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Read More
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Exelixis: A Notable Quarter
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Positive
Exelixis just delivered a strong Q1 beat, raised 2025 guidance, and continues to benefit from robust Cabometyx sales and share buybacks. The company is transitioning to zanzalintinib as its next flagship drug, but pivotal trial success remains uncertain, and skepticism persists among analysts. The company has a rock-solid balance sheet with some $1.75 billion in cash and no long-term debt.
Read More
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis' first-quarter earnings and sales beat estimates as lead drug Cabometyx maintains momentum. The company raises its sales guidance for 2025.
Read More
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top -and-bottom-line estimates for Exelixis (EXEL), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Read More
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors will likely focus on the demand for Cabometyx and pipeline updates when EXEL reports Q1 results.
Read More
Here's Why Exelixis (EXEL) is a Strong Value Stock
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
EXEL or TECH: Which Is the Better Value Stock Right Now?
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Read More
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
Published: February 21, 2025 by: Benzinga
Sentiment: Positive
On Friday, Exelixis, Inc. EXEL authorized repurchasing up to an additional $500 million of the company's common stock before December 31, 2025.
Read More
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Read More
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis beats on Q4 earnings and sales as lead drug Cabometyx maintains momentum. The company reiterates its guidance for 2025.
Read More
Exelixis, Inc. (EXEL) Q4 2024 Earnings Call Transcript
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Exelixis, Inc. (NASDAQ:EXEL ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs & Investor Relations Mike Morrissey - President & Chief Executive Officer Chris Senner - Chief Financial Officer PJ Haley - Executive Vice President, Commercial Amy Peterson - Chief Medical Officer Dana Aftab - Chief Scientific Officer Conference Call Participants Asthika Goonewardene - Truist Sean Laaman - Morgan Stanley David Lebowitz - Citi Gregory Renza - RBC Capital Markets Eva Fortea-Verdejo - Wells Fargo Jason Gerberry - Bank of America Securities Andy Hsieh - William Blair …
Read More
Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Exelixis Posts 63.7% Profit Surge
Published: February 11, 2025 by: The Motley Fool
Sentiment: Neutral
Exelixis (EXEL -2.06%), a biopharmaceutical company specializing in oncology treatments, released its fourth-quarter 2024 financial results, revealing a substantial rise in both revenue and earnings. Announced on Feb. 11, 2025, the earnings release showcased Exelixis's performance amidst a challenging oncology landscape, with revenues surpassing year-over-year figures by 18.2%.
Read More
About Exelixis, Inc. (EXEL)
- IPO Date 2000-04-17
- Website https://www.exelixis.com
- Industry Biotechnology
- CEO Dr. Michael M. Morrissey Ph.D.
- Employees 1147